Perspective Therapeutics News

Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Perspective Therapeutics (CATX) and Glaukos (GKOS)

TipRanksMay 28 07:40 ET

Buy Rating Affirmed for Perspective Therapeutics Amid Promising Competitor Data and Treatment Innovations

TipRanksMay 24 10:05 ET

Perspective Therapeutics Analyst Ratings

BenzingaMay 16 12:26 ET

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Unicycive Therapeutics (UNCY)

TipRanksMay 15 13:30 ET

Perspective Therapeutics Analyst Ratings

BenzingaMay 14 08:01 ET

Perspective Therapeutics Analyst Ratings

BenzingaMay 9 06:21 ET

Perspective Therapeutics Analyst Ratings

BenzingaApr 9 13:46 ET

Perspective Therapeutics Analyst Ratings

BenzingaApr 1 09:26 ET

Analysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Perspective Therapeutics (CATX)

TipRanksMar 27 12:30 ET

Buy Rating Affirmed for Perspective Therapeutics Amid Clinical Success and Strategic Partnerships

TipRanksMar 21 07:27 ET

Perspective Therapeutics Analyst Ratings

BenzingaMar 19 09:01 ET

Oppenheimer Reiterates Outperform on Perspective Therapeutics, Maintains $1.2 Price Target

BenzingaMar 19 09:02 ET

Analysts Are Bullish on These Healthcare Stocks: Perspective Therapeutics (CATX), Neurogene (NGNE)

TipRanksMar 19 08:03 ET

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Perspective Therapeutics (CATX)

TipRanksMar 6 07:50 ET

Perspective Therapeutics Analyst Ratings

BenzingaJan 26 11:37 ET

B. Riley Starts Perspective Therapeutics With Buy Rating, $1.20 Price Target; Says Well-Positioned to Break Out of Biotech Pack

MT NewswiresJan 26 08:03 ET

Oppenheimer Remains a Buy on Perspective Therapeutics (CATX)

TipRanksJan 22 14:47 ET

Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Perspective Therapeutics (CATX)

TipRanksDec 18, 2023 10:40 ET

Buy Rating Reaffirmed for Perspective Therapeutics Amid Promising Clinical Developments

TipRanksNov 30, 2023 16:55 ET

Oppenheimer Sticks to Their Buy Rating for Perspective Therapeutics (CATX)

TipRanksNov 16, 2023 07:56 ET